目的观察ATM蛋白激酶-检测点激酶2(ATM-Chk2)通路在氟抑制大鼠曲细精管上皮支持细胞增殖中的作用。方法将18日龄SPF级雄性SD大鼠曲细精管上皮支持细胞分别暴露于含0(对照)、0.25、0.50、1.00、2.00、4.00 mmol/L氟化钠的血清培养基。分...目的观察ATM蛋白激酶-检测点激酶2(ATM-Chk2)通路在氟抑制大鼠曲细精管上皮支持细胞增殖中的作用。方法将18日龄SPF级雄性SD大鼠曲细精管上皮支持细胞分别暴露于含0(对照)、0.25、0.50、1.00、2.00、4.00 mmol/L氟化钠的血清培养基。分别于染毒24、48、72 h,采用MTT法测定支持细胞的增殖情况;于染毒24 h,采用实时荧光定量PCR技术检测支持细胞内ATM、Chk2 m RNA的表达水平。结果与对照组比较,染毒24、48、72 h时,4.00 mmol/L氟化钠染毒组大鼠曲细精管上皮支持细胞的抑制率均较高,差异有统计学意义(P<0.05);且随着氟化钠染毒剂量的升高和染毒时间的延长,氟对曲细精管上皮支持细胞的抑制率均呈上升趋势。与对照组比较,1、2 mmol/L氟化钠染毒组曲细精管上皮支持细胞ATM和Chk2 m RNA的表达水平均升高,而4 mmol/L氟化钠染毒组ATM和Chk2 m RNA的表达水平均降低,差异有统计学意义(P<0.05);且随着氟化钠染毒剂量的升高,曲细精管上皮支持细胞ATM、Chk2 m RNA的表达水平均呈下降趋势。结论不同剂量氟抑制生殖细胞增殖可能是通过干扰曲细精管上皮支持细胞中DNA损伤检验点ATM、Chk2的表达而实现的。展开更多
The DNA damage response （DDR） is activated when DNA is altered by intrinsic or extrinsic agents. This pathway is a complex signaling network and plays important roles in genome stability, tumor transformation, and c...The DNA damage response （DDR） is activated when DNA is altered by intrinsic or extrinsic agents. This pathway is a complex signaling network and plays important roles in genome stability, tumor transformation, and cell cycle regulation. Human papillomaviruses （HPVs） are the main etiological agents of cervical cancer. Cervical cancer ranks as the fourth most common cancer among women and the second most frequent cause of cancer-related death worldwide. Over 200 types of HPVs have been identified and about one third of these infect the genital tract. The HPV life cycle is associated with epithelial differentiation. Recent studies have shown that HPVs deregulate the DDR to achieve a productive life cycle. In this review, I summarize current findings about how HPVs mediate the ataxia- telangiectasia mutated kinase （ATM） and the ATM- and RAD3-related kinase （ATR） DDRs, and focus on the roles that ATM and ATR signalings play in HPV viral replication. In addition, I demonstrate that the signal transducer and acti- vator of transcription-5 （STAT）-5, an important immune regulator, can promote ATM and ATR activations through different mechanisms. These findings may provide novel opportunities for development of new therapeutic targets for HPV-related cancers.展开更多
Technologies that measure activation of components of the DNA damage response (DDR) have applications in exposure assessment and personalized medicine. The DDR and associated DNA repair pathways encompass hundreds of ...Technologies that measure activation of components of the DNA damage response (DDR) have applications in exposure assessment and personalized medicine. The DDR and associated DNA repair pathways encompass hundreds of proteins, making detailed measurement of activation technically challenging and laborious. The purpose of our study was to develop protein-specific assays for certain DDR components on a high-throughput electrochemiluminescence (ECL)-based platform. We developed five working assay pairs for ataxia telangiectasia mutated (ATM), checkpoint kinase 2 (CHK2), phosphorylated-ATM S1981, phosphorylated-CHK2 T68 and phosphorylated-tumor protein p53 (p53) S15. We validated the ECL results against traditional immunoblot and γ-H2AX foci measures in cell and cancer models. In an effort to test the ECL-based technology in a clinical setting, we utilized peripheral blood mononuclear cells (PBMCs) from patients undergoing computed tomography (CT) scans. CT scans represent both a valuable medical imaging diagnostic and a controlled environmental exposure to ionizing radiation for research studies, as they deliver ~2 to 31 millisieverts (mSv) and are known to activate DDR components. In this study, we show that ECL-based technology can measure the basal and damage-induced levels of DDR components in patient PBMC samples. Using a blinded study design and patient matched pre- and post CT scan samples, we show that ECL-derived data can consistently (94% of the time, 15/16 patients) identify PBMCs that have been exposed to low dose ionizing radiation associated with CT scans. Ultimately, the results of our pilot clinical study support the idea that ECL-based technology is applicable for use in clinical and population cohorts that study components of the DDR.展开更多
文摘目的观察ATM蛋白激酶-检测点激酶2(ATM-Chk2)通路在氟抑制大鼠曲细精管上皮支持细胞增殖中的作用。方法将18日龄SPF级雄性SD大鼠曲细精管上皮支持细胞分别暴露于含0(对照)、0.25、0.50、1.00、2.00、4.00 mmol/L氟化钠的血清培养基。分别于染毒24、48、72 h,采用MTT法测定支持细胞的增殖情况;于染毒24 h,采用实时荧光定量PCR技术检测支持细胞内ATM、Chk2 m RNA的表达水平。结果与对照组比较,染毒24、48、72 h时,4.00 mmol/L氟化钠染毒组大鼠曲细精管上皮支持细胞的抑制率均较高,差异有统计学意义(P<0.05);且随着氟化钠染毒剂量的升高和染毒时间的延长,氟对曲细精管上皮支持细胞的抑制率均呈上升趋势。与对照组比较,1、2 mmol/L氟化钠染毒组曲细精管上皮支持细胞ATM和Chk2 m RNA的表达水平均升高,而4 mmol/L氟化钠染毒组ATM和Chk2 m RNA的表达水平均降低,差异有统计学意义(P<0.05);且随着氟化钠染毒剂量的升高,曲细精管上皮支持细胞ATM、Chk2 m RNA的表达水平均呈下降趋势。结论不同剂量氟抑制生殖细胞增殖可能是通过干扰曲细精管上皮支持细胞中DNA损伤检验点ATM、Chk2的表达而实现的。
文摘The DNA damage response （DDR） is activated when DNA is altered by intrinsic or extrinsic agents. This pathway is a complex signaling network and plays important roles in genome stability, tumor transformation, and cell cycle regulation. Human papillomaviruses （HPVs） are the main etiological agents of cervical cancer. Cervical cancer ranks as the fourth most common cancer among women and the second most frequent cause of cancer-related death worldwide. Over 200 types of HPVs have been identified and about one third of these infect the genital tract. The HPV life cycle is associated with epithelial differentiation. Recent studies have shown that HPVs deregulate the DDR to achieve a productive life cycle. In this review, I summarize current findings about how HPVs mediate the ataxia- telangiectasia mutated kinase （ATM） and the ATM- and RAD3-related kinase （ATR） DDRs, and focus on the roles that ATM and ATR signalings play in HPV viral replication. In addition, I demonstrate that the signal transducer and acti- vator of transcription-5 （STAT）-5, an important immune regulator, can promote ATM and ATR activations through different mechanisms. These findings may provide novel opportunities for development of new therapeutic targets for HPV-related cancers.
文摘Technologies that measure activation of components of the DNA damage response (DDR) have applications in exposure assessment and personalized medicine. The DDR and associated DNA repair pathways encompass hundreds of proteins, making detailed measurement of activation technically challenging and laborious. The purpose of our study was to develop protein-specific assays for certain DDR components on a high-throughput electrochemiluminescence (ECL)-based platform. We developed five working assay pairs for ataxia telangiectasia mutated (ATM), checkpoint kinase 2 (CHK2), phosphorylated-ATM S1981, phosphorylated-CHK2 T68 and phosphorylated-tumor protein p53 (p53) S15. We validated the ECL results against traditional immunoblot and γ-H2AX foci measures in cell and cancer models. In an effort to test the ECL-based technology in a clinical setting, we utilized peripheral blood mononuclear cells (PBMCs) from patients undergoing computed tomography (CT) scans. CT scans represent both a valuable medical imaging diagnostic and a controlled environmental exposure to ionizing radiation for research studies, as they deliver ~2 to 31 millisieverts (mSv) and are known to activate DDR components. In this study, we show that ECL-based technology can measure the basal and damage-induced levels of DDR components in patient PBMC samples. Using a blinded study design and patient matched pre- and post CT scan samples, we show that ECL-derived data can consistently (94% of the time, 15/16 patients) identify PBMCs that have been exposed to low dose ionizing radiation associated with CT scans. Ultimately, the results of our pilot clinical study support the idea that ECL-based technology is applicable for use in clinical and population cohorts that study components of the DDR.
